Related Experiment Videos
Newer immunosuppressive drugs: a review
J F Gummert1, T Ikonen, R E Morris
1Department of Cardiothoracic Surgery, Stanford University Medical School, California 94305-5407, USA.
Journal of the American Society of Nephrology : JASN
|June 11, 1999
Summary
New immunosuppressive drugs for transplantation significantly reduce acute rejection without increasing infection or malignancy risks. This allows for personalized immunosuppressive therapy tailored to individual patient needs.
Area of Science:
- Immunology
- Pharmacology
- Transplantation Medicine
Background:
- Recent advancements have introduced novel immunosuppressive drugs for clinical transplantation.
- Key drugs reviewed include leflunomide, mycophenolate mofetil, sirolimus, and tacrolimus.
- Development in monoclonal antibodies, such as anti-interleukin-2 receptor antibodies, is also highlighted.
Purpose of the Study:
- To review recently developed immunosuppressive drugs for transplantation.
- To analyze the efficacy and safety profiles of these new agents.
- To discuss the potential for combination therapies and personalized immunosuppression.
Main Methods:
- Review of clinical trial data for new immunosuppressants.
- Analysis of efficacy in reducing allograft rejection.
- Evaluation of safety data regarding infection and malignancy rates.
Main Results:
- New immunosuppressants demonstrate a statistically significant reduction in acute rejection.
- These drugs have not shown a proportional increase in infection or malignancy rates.
- Combination therapies can be designed to target different immune pathways with reduced toxicity.
Conclusions:
- Novel immunosuppressive drugs offer improved outcomes in transplantation.
- Personalized immunosuppressive regimens can be tailored to individual patient needs.
- Careful selection of drug combinations minimizes toxicity while maximizing efficacy.